Bambusa Therapeutics, Inc. (NASDAQ:BBTX – Get Free Report) major shareholder Salvia Investment Gmbh bought 375,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were acquired at an average price of $16.00 per share, with a total value of $6,000,000.00. Following the completion of the transaction, the insider directly owned 9,264,301 shares of the company’s stock, valued at $148,228,816. This trade represents a 4.22% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Bambusa Therapeutics Stock Up 6.7%
BBTX stock traded up $1.01 during midday trading on Monday, reaching $16.00. 433,191 shares of the company’s stock traded hands. Bambusa Therapeutics, Inc. has a 52-week low of $13.60 and a 52-week high of $16.06.
Recommended Stories
- Five stocks we like better than Bambusa Therapeutics
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Bambusa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bambusa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
